

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Acotec Scientific Holdings Limited
先瑞達醫療科技控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6669)

POSITIVE PROFIT ALERT

This announcement is made by Acotec Scientific Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) would like to inform the shareholders (the “**Shareholders**”) and potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2021 (the “**Year 2021**”) and other information currently available, the Group expects to record:

- (i) revenue of approximately RMB300 million to RMB303 million, representing an increase of approximately 54.7% to 56.2% as compared to that of the year ended December 31, 2020 (the “**Year 2020**”);
- (ii) gross profit of approximately RMB260 million to RMB268 million, representing an increase of approximately 58.7% to 63.6% as compared to that of the Year 2020; and
- (iii) adjusted net profit¹ of approximately RMB38 million to RMB46 million, representing an increase of approximately 111.3% to 155.8% as compared to that of the Year 2020.

¹ The Company uses adjusted net profit as a non-IFRS measure by eliminating potential impact of certain non-recurring or one-off expenses that do not affect the Group’s ongoing operating performance, including listing expenses, loss on fair value change of preferred shares, net foreign exchange loss on the translation of listing proceeds, deferred tax asset derecognition and share-based payments expenses.

Such expected increases in revenue, gross profit and adjusted net profit are primarily driven by the growth of the Group's business, in particular (i) the increase in revenue generated from the sales of AcoArt Orchid® & Dhalia™ and (ii) the revenue generated from the sales of AcoArt Tulip™ & Litos™ which was commercialized in 2021.

The Company is in the process of finalizing the consolidated annual results for the Year 2021. The information contained in this announcement is only based on the preliminary assessment by the management of the Company with reference to the unaudited management accounts of the Group and other information currently available which may be subject to change and may differ from the figures to be disclosed in the audited consolidated financial statements to be published by the Company. Such information has not been audited or reviewed by the Company's auditors or the audit committee of the Company. Shareholders and potential investors should refer to the annual results announcement of the Company for the Year 2021, which is expected to be published in March 2022, for details of the performance of the Group.

Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

By Order of the Board
Acotec Scientific Holdings Limited
Jing LI
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, January 23, 2022

As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Ke TANG and Mr. Chen CHEN, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.